Logo image of ECX.DE

EPIGENOMICS AG (ECX.DE) Stock Fundamental Analysis

FRA:ECX - Deutsche Boerse Ag - DE000A37FT41 - Common Stock - Currency: EUR

0.7  -0.09 (-11.17%)

Fundamental Rating

2

Taking everything into account, ECX scores 2 out of 10 in our fundamental rating. ECX was compared to 73 industry peers in the Biotechnology industry. ECX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ECX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ECX had negative earnings in the past year.
ECX had a negative operating cash flow in the past year.
ECX had negative earnings in each of the past 5 years.
ECX had a negative operating cash flow in each of the past 5 years.
ECX.DE Yearly Net Income VS EBIT VS OCF VS FCFECX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -386.29%, ECX is not doing good in the industry: 92.00% of the companies in the same industry are doing better.
With a Return On Equity value of -853.33%, ECX is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -386.29%
ROE -853.33%
ROIC N/A
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
ECX.DE Yearly ROA, ROE, ROICECX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 76.56%, ECX is in the better half of the industry, outperforming 78.67% of the companies in the same industry.
In the last couple of years the Gross Margin of ECX has declined.
The Profit Margin and Operating Margin are not available for ECX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
ECX.DE Yearly Profit, Operating, Gross MarginsECX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ECX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ECX has more shares outstanding than it did 1 year ago.
ECX has a worse debt/assets ratio than last year.
ECX.DE Yearly Shares OutstandingECX.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
ECX.DE Yearly Total Debt VS Total AssetsECX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -44.22, we must say that ECX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ECX (-44.22) is worse than 93.33% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that ECX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.06, ECX is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -44.22
ROIC/WACCN/A
WACC3.9%
ECX.DE Yearly LT Debt VS Equity VS FCFECX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

ECX has a Current Ratio of 1.93. This is a normal value and indicates that ECX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.93, ECX is in line with its industry, outperforming 48.00% of the companies in the same industry.
A Quick Ratio of 1.93 indicates that ECX should not have too much problems paying its short term obligations.
ECX has a Quick ratio (1.93) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
ECX.DE Yearly Current Assets VS Current LiabilitesECX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ECX have decreased strongly by -7359.64% in the last year.
ECX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.80%.
Measured over the past years, ECX shows a very negative growth in Revenue. The Revenue has been decreasing by -23.61% on average per year.
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%

3.2 Future

Based on estimates for the next years, ECX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.99% on average per year.
ECX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.06% yearly.
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ECX.DE Yearly Revenue VS EstimatesECX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
ECX.DE Yearly EPS VS EstimatesECX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ECX. In the last year negative earnings were reported.
Also next year ECX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ECX.DE Price Earnings VS Forward Price EarningsECX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECX.DE Per share dataECX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

A more expensive valuation may be justified as ECX's earnings are expected to grow with 25.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.12%
EPS Next 3Y25.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ECX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EPIGENOMICS AG

FRA:ECX (6/27/2024, 7:00:00 PM)

0.7

-0.09 (-11.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-27 2024-05-27
Earnings (Next)09-30 2024-09-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.90K
Analysts80
Price Target16.32 (2231.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA N/A
EPS(TTM)-17.68
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-397.44
FCFYN/A
OCF(TTM)-367.27
OCFYN/A
SpS13.12
BVpS55.92
TBVpS54.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -386.29%
ROE -853.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.56%
FCFM N/A
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.27%
Cap/Sales 229.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -44.22
F-Score3
WACC3.9%
ROIC/WACCN/A
Cap/Depr(3y)64.84%
Cap/Depr(5y)50.54%
Cap/Sales(3y)94.83%
Cap/Sales(5y)60.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%
EBIT growth 1Y-157.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.62%
EBIT Next 3Y25.99%
EBIT Next 5Y-7.05%
FCF growth 1Y-63.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.5%
OCF growth 3YN/A
OCF growth 5YN/A